Literature DB >> 26884654

The Post-Surgical Long-Term Behaviour of Lung Carcinoid Tumours.

Antonio Tancredi1, Lucia Anna Muscarella2, Annamaria la Torre2, Roberto Scaramuzzi3, Vanna Maria Valori4, Vito Michele Fazio2, Gerardo Scaramuzzi3.   

Abstract

Here, we report a retrospective evaluation of long-term behaviour of lung carcinoids after surgery. A total of 23 patients (17 with typical pulmonary carcinoids and 6 with atypical pulmonary carcinoids) were enrolled in our hospital from April 1994 to July 2009. All patients underwent intervention at the Unit of Surgery and then were followed at the Unit of Oncology. The standard protocol for patient monitoring consisted of follow-up at 3 months after surgery, 6 months after first control and annually for 5 years. The follow-up evaluations consisted in blood tests, imaging of chest and abdomen, bone scintigraphy, and brain computed tomography. In case of disease recurrence, patients underwent chemotherapy (etoposide, carboplatin) and radiotherapy. All patients were followed for a mean of follow-up period of 100 months, ranging between 20 and 203 months. In the group of typical carcinoid, the observed recurrence rate at 5 years was zero, at 10 years was 5.8 %, whereas the observed mortality rate at 5 and 10 years was zero. In the group of atypical carcinoid, both the recurrence rate and the mortality rate at 5 and 10 years were 16.6 %. A statistical significant difference (p = 0.002) in the recurrence rate between stage I and stage II was observed. The overall prognosis of pulmonary carcinoids was favourable, and the typical carcinoids presented a better prognosis than the atypical ones. The stage at time of diagnosis could be considered as a predictive prognostic factor.

Entities:  

Keywords:  Carcinoid tumours; Long term follow-up; Lung cancer; Lymph node metastasis; Tumour behaviour

Year:  2015        PMID: 26884654      PMCID: PMC4744214          DOI: 10.1007/s12262-015-1290-z

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  18 in total

1.  Long-term outcome of bronchoscopically resected endobronchial typical carcinoid tumors.

Authors:  Heyman Luckraz; Khalid Amer; Lynne Thomas; Allen Gibbs; Eric G Butchart
Journal:  J Thorac Cardiovasc Surg       Date:  2006-07       Impact factor: 5.209

Review 2.  Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

Authors:  N Fazio; F de Braud; G Delle Fave; K Öberg
Journal:  Ann Oncol       Date:  2006-06-23       Impact factor: 32.976

Review 3.  Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.

Authors:  I M Modlin; M Pavel; M Kidd; B I Gustafsson
Journal:  Aliment Pharmacol Ther       Date:  2009-10-21       Impact factor: 8.171

4.  Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids.

Authors:  Hes A P Brokx; Elle K Risse; Marinus A Paul; Katrien Grünberg; Richard P Golding; Peter W A Kunst; Jan-Peter Eerenberg; Johan C van Mourik; Pieter E Postmus; Wolter J Mooi; Tom G Sutedja
Journal:  J Thorac Cardiovasc Surg       Date:  2007-04       Impact factor: 5.209

5.  Typical and atypical carcinoid tumours: 20-year experience with 89 patients.

Authors:  F Davini; A Gonfiotti; C Comin; A Caldarella; F Mannini; A Janni
Journal:  J Cardiovasc Surg (Torino)       Date:  2008-10-24       Impact factor: 1.888

Review 6.  Bronchial carcinoid tumors.

Authors:  D G Davila; W F Dunn; H D Tazelaar; P C Pairolero
Journal:  Mayo Clin Proc       Date:  1993-08       Impact factor: 7.616

Review 7.  Is sublobar resection equivalent to lobectomy for surgical management of peripheral carcinoid?

Authors:  Jonathan Afoke; Carol Tan; Ian Hunt; Mustafa Zakkar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-03-06

8.  Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Authors:  D B Smith; J H Scarffe; J Wagstaff; R J Johnston
Journal:  Cancer Treat Rep       Date:  1987-12

Review 9.  [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].

Authors:  Renata Langfort; Piotr Rudziński; Barbara Burakowska
Journal:  Pneumonol Alergol Pol       Date:  2010

10.  Determination of safe margin in the surgical pathologic specimens of non-small cell carcinoma of the lung.

Authors:  Iraj Feizi; Mohsen Sokouti; Samad E J Golzari; Morteza Gojazede; Mohammad Reza Farahnak; Shahriar Hashemzadeh; Mohammad Hossein Rahimi-Rad
Journal:  Pneumologia       Date:  2013 Jan-Mar
View more
  1 in total

Review 1.  Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors.

Authors:  Philip T Sobash; Asad Ullah; Nagla Abdel Karim
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.